Arnon Lavie

age ~59

from Chicago, IL

Get Report
Also known as:
  • Astrid Lavie
  • Jason Ketchum
Phone and address:
612 Laflin St, Chicago, IL 60607
3122430173
Related to:
Connected to:

Arnon Lavie Phones & Addresses

  • 612 Laflin St, Chicago, IL 60607 • 3122430173
  • 2468 Orchard St, Chicago, IL 60614 • 7732810289
  • Evanston, IL
  • Miami, FL
  • 612 S Laflin St UNIT D, Chicago, IL 60607 • 3122590925

Work

  • Company:
    Max planck institute for molecular physiology
    Aug 1994 to May 1999
  • Position:
    Post-doctoral fellow

Education

  • Degree:
    Doctorates, Doctor of Philosophy
  • School / High School:
    Brandeis University
    1989 to 1994
  • Specialities:
    Biochemistry, Chemistry

Emails

a***[email protected]

Industries

Higher Education

Resumes

Arnon Lavie Photo 1

Professor

view source
Location:
14604 Maple Ln, Dolton, IL 60419
Industry:
Higher Education
Work:
Max Planck Institute For Molecular Physiology Aug 1994 - May 1999
Post-Doctoral Fellow
University of Illinois at Chicago Aug 1994 - May 1999
Professor
Education:
Brandeis University 1989 - 1994
Doctorates, Doctor of Philosophy, Biochemistry, Chemistry The American School In Japan
Tel Aviv University

Us Patents

  • Use Of Specifically Engineered Enzymes To Enhance The Efficacy Of Prodrugs

    view source
  • US Patent:
    7858745, Dec 28, 2010
  • Filed:
    Jun 8, 2007
  • Appl. No.:
    11/760399
  • Inventors:
    Arnon Lavie - Chicago IL, US
    Manfred Konrad - Goettingen, DE
    Farhad Ravandi - Houston TX, US
  • Assignee:
    The Board of Trustees of the University of Illinois - Urbana IL
  • International Classification:
    C07K 14/00
    C12N 15/00
  • US Classification:
    530350, 514 2, 435 681
  • Abstract:
    The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.

  • Use Of Specifically Engineered Enzymes To Enhance The Efficacy Of Prodrugs

    view source
  • US Patent:
    8349318, Jan 8, 2013
  • Filed:
    May 18, 2009
  • Appl. No.:
    12/993660
  • Inventors:
    Arnon Lavie - Chicago IL, US
    Manfred Konrad - Göttingen, DE
  • Assignee:
    The Board of Trustees of the University of Illinois - Urbana IL
  • International Classification:
    A61K 38/54
    A61K 39/00
    G01N 33/53
    C12P 21/06
    C12N 9/96
    C07H 21/04
  • US Classification:
    424 943, 4241781, 435 71, 435 691, 435188, 4353201, 5303671, 536 231
  • Abstract:
    The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with altered or enhanced activity and broader substrate specificity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activities. Furthermore, the invention provides antibody-conjugated enzymes, pharmaceutical composition and kit containing the same, that can be specifically delivered to tumor cells.

  • Use Of Specifically Engineered Enzymes To Enhance The Efficacy Of Prodrugs

    view source
  • US Patent:
    20050008648, Jan 13, 2005
  • Filed:
    Mar 1, 2004
  • Appl. No.:
    10/791155
  • Inventors:
    Arnon Lavie - Chicago IL, US
    Manfred Konrad - Goettingen, DE
    Farhad Ravandi - Houston TX, US
  • International Classification:
    A61K039/395
    C12N009/00
  • US Classification:
    424178100, 435188500
  • Abstract:
    The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.

  • Thymidylate Kinase Mutants And Uses Thereof

    view source
  • US Patent:
    20090068158, Mar 12, 2009
  • Filed:
    Mar 20, 2008
  • Appl. No.:
    12/052565
  • Inventors:
    Jeffrey A. Medin - Toronto, CA
    Arnon Lavie - Chicago IL, US
    Daniel H. Fowler - Bethesda MD, US
    Boro Dropulic - Ellicott City MD, US
  • International Classification:
    A61K 35/12
    A61K 31/7088
    C12N 15/87
    C12N 5/10
    C12N 15/63
  • US Classification:
    424 9321, 514 44, 435455, 4353201, 435325
  • Abstract:
    The invention relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk. The invention also relates to use of these compositions in methods of treatment of diseaseuuius such as graft versus host disease and cancer.

  • Thymidylate Kinase Mutants And Uses Thereof

    view source
  • US Patent:
    20090074733, Mar 19, 2009
  • Filed:
    Nov 14, 2006
  • Appl. No.:
    11/559757
  • Inventors:
    Jeffrey A. Medin - Toronto, CA
    Arnon Lavie - Chicago IL, US
    Daniel H. Fowler - Bethesda MD, US
  • International Classification:
    A61K 35/12
    C12N 15/00
    C12N 5/06
    A61P 43/00
    C12N 15/87
  • US Classification:
    424 9321, 4353201, 435455, 435375, 536 232
  • Abstract:
    The invention relates to a composition comprising:The invention also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.

  • Thymidylate Kinase Mutants And Uses Thereof

    view source
  • US Patent:
    20110014165, Jan 20, 2011
  • Filed:
    Jul 26, 2010
  • Appl. No.:
    12/843238
  • Inventors:
    Jeffrey A. Medin - Toronto, CA
    Arnon Lavie - Chicago IL, US
    Daniel H. Fowler - Bethesda MD, US
  • International Classification:
    A61K 35/12
    A61K 35/14
    A61K 31/7072
    C12N 5/071
    A61K 48/00
    A61P 35/00
  • US Classification:
    424 9321, 514 50, 435375, 514 44 R
  • Abstract:
    The invention relates to a composition comprising a stably integrating delivery vector; and a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk. The invention also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.

  • Deoxycytidine Kinase Inhibitors

    view source
  • US Patent:
    20170204090, Jul 20, 2017
  • Filed:
    Jan 31, 2017
  • Appl. No.:
    15/421258
  • Inventors:
    - OAKLAND CA, US
    - URBANA IL, US
    RAYMOND M. GIPSON - LOS ANGELES CA, US
    JUE WANG - LOS ANGELES CA, US
    ARNON LAVIE - CHICAGO IL, US
    JENNIFER M. MURPHY - LOS ANGELES CA, US
    DAVID A. NATHANSON - LOS ANGELES CA, US
    MICHAEL E. JUNG - LOS ANGELES CA, US
  • International Classification:
    C07D 417/14
    C07B 59/00
    C07D 417/12
  • Abstract:
    Provided herein are compounds that bind to dCK and methods for treating cancer.

  • Deoxycytidine Kinase Inhibitors

    view source
  • US Patent:
    20160237076, Aug 18, 2016
  • Filed:
    Jan 11, 2016
  • Appl. No.:
    14/992396
  • Inventors:
    - Oakland CA, US
    Zheng Li - Oakland CA, US
    Raymond M. Gipson - Los Angeles CA, US
    Jue Wang - Los Angeles CA, US
    Arnon Lavie - Chicago IL, US
    Jennifer M. Murphy - Los Angeles CA, US
    David A. Nathanson - Los Angeles CA, US
    Michael E. Jung - Los Angeles CA, US
  • International Classification:
    C07D 417/12
    C07D 413/12
    C07B 59/00
  • Abstract:
    Provided herein are compounds that bind to dCK and methods for treating cancer.

Googleplus

Arnon Lavie Photo 2

Arnon Lavie

Youtube

Nombres chapitre 21

Nombres chapitre 21

1 Le roi d'Arad, Cananen, qui habitait le midi, apprit qu'Isral venait...

  • Category:
    Education
  • Uploaded:
    08 Dec, 2010
  • Duration:
    6m 48s
Get Report for Arnon Lavie from Chicago, IL, age ~59
Control profile